Forbes Medi-Tech Initiates Toxicity Study on FM-VP4 to Support US Phase II Trial for Cholesterol-Lowering Drug.
Business Wire (February 01, 2005)
Permanent Link:
http://vlex.com/vid/medi-toxicity-cholesterol-lowering-54797688
Id. vLex: VLEX-54797688
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
Forbes Medi-Tech Initiates Toxicity Study on FM-VP4 to Support US Phase II Trial for Cholesterol-Lowering Drug.
VANCOUVER, British Columbia -- Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) today announced that it has commenced a 90-day toxicity study for its cholesterol-lowering drug, FM-VP4. This study is required to support an extended US...
Try vLex for FREE for 3 days
Access legal information from United States including:
- Constitutions
- Forms and Contracts
- Legal Books and Journals
- Case Law
- News and Business
- Regulations
- U.S. Code
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here
